To investigate the efficacy and safety of hydroxychloroquine in IgA nephropathy based on PPK model

Efficacy and safety evaluation of hydroxychloroquine in the treatment of IgA nephropathy

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052910

Enrollment

Unknown

Registered

2021-11-06

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

Experimental group:RAASi + hydroxychloroquine

Cotrol group :RAASi+placebo

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 ~ 75 years; 2. Primary IgAN was diagnosed by pathology (light microscope + electron microscope); 3. Estimated glomerular filtration rate (eGFR) over 30 mL/(min?1.73m2); 4. Urine protein was 0.75 to 3.5g/d at least 3 months after receiving the maximum dose of RAAS inhibitors.

Exclusion criteria

Exclusion criteria: 1. Systemic immunosuppressive therapy was used one year ago; 2. Glucocorticoids are needed in patients with crescent IgAN or microlesions with IgA deposition; 3. Current or planned pregnancy or breastfeeding; 4. There are contraindications to HCQ treatment.

Design outcomes

Primary

Measure	Time frame
24-hour proteinuria;	—

Secondary

Measure	Time frame
Adverse reactions;	—

Countries

China

Contacts

Public ContactYang Ting

Drum Tower Hospital Affiliated to Nanjing University Medical School

455814589@qq.com+86 15850628040

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026